[{"orgOrder":0,"company":"NeuroGenesis","sponsor":"Hadassah Medical Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuroGenesis and Hadassah Medical Center Report Positive NF-L Biomarker Results from a Phase 2 Study in Progressive Multiple Sclerosis Treated with NG-01 Cells Therapy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"NeuroGenesis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuroGenesis Reports Positive Results from Phase 2 Extension Study in Progressive Multiple Sclerosis Treated with NG-01 Cell Therapy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"}]
Find Clinical Drug Pipeline Developments & Deals by NeuroGenesis
NG-01 is a proprietary population of autologous bone marrow-derived stem cells designed to secrete high levels of remyelinating and neurotrophic factors (NG-01) at the central nervous system site of injury. It is being evaluated for the treatment of multiple sclerosis.
Results published in Stem Cells Translational Medicine show significant reduction of NF-L, a biomarker for neuronal damage, in patients with progressive multiple sclerosis after treatment with NG-01 stem cells.